Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · IEX Real-Time Price · USD
31.09 -1.28 (-3.95%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap2.18B
Revenue (ttm)37.87M
Net Income (ttm)-278.39M
Shares Out70.25M
EPS (ttm)-4.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume635,465
Open32.24
Previous Close32.37
Day's Range31.06 - 33.00
52-Week Range22.36 - 49.10
Beta0.84
AnalystsStrong Buy
Price Target64.40 (+107.1%)
Earnings DateFeb 22, 2022

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combi...

IndustryBiotechnology
IPO DateMar 15, 2018
Employees236
Stock ExchangeNYSE
Ticker SymbolRCUS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 64.40, which is an increase of 107.14% from the latest price.

Price Target
$64.40
(107.14% upside)
Analyst Consensus: Strong Buy

News

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

1 week ago - Business Wire

Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for peo...

1 week ago - Business Wire

Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research C...

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gilead's option exercises to three pr...

Other symbols:GILD
1 month ago - Business Wire

Why Arcus Biosciences Stock Vaulted Higher in November

Arcus was one of the few winners in the turbulent biotech space last month.

1 month ago - The Motley Fool

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences' Anti-TIGIT Program in Japan and ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for peo...

1 month ago - Business Wire

Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for pe...

2 months ago - Business Wire

Why Are Arcus Biosciences Shares Trading Higher Today?

Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT molecules, domvanalimab, and AB308, as well as e...

2 months ago - Benzinga

Why Arcus Biosciences Stock Is On Fire Today

Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.

2 months ago - The Motley Fool

Arcus Biosciences shares rocket premarket after Gilead exercises options for 3 cancer programs for $725 million

Shares of Arcus Biosciences Inc. RCUS, -1.10% rocketed 21% in premarket trading Thursday, after Gilead Sciences Inc. GILD, +0.85% said it's exercising options to three programs in the company's clinical...

Other symbols:GILD
2 months ago - Market Watch

Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that Gilead has exercised its options to three progr...

Other symbols:GILD
2 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 1.77% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for peo...

2 months ago - Business Wire

Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for peop...

2 months ago - Business Wire

Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q3 Earnings Expected to Decline

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

New Strong Sell Stocks for October 15th

BWB, CDE, ONEM, RCUS, and TMHC have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2021

Other symbols:BWBCDEONEMTMHC
3 months ago - Zacks Investment Research

Arcus Biosciences to Participate at Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...

4 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -41.56% and -48.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results fo...

5 months ago - Business Wire

Arcus Biosciences to Participate at the 2021 Wedbush PacGrow Virtual Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...

5 months ago - Business Wire

Will Arcus Biosciences, Inc. (RCUS) Report Negative Q2 Earnings? What You Should Know

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Arcus Biosciences to Report Second Quarter 2021 Financial Results & Recent Corporate Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company wi...

5 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) Stock Jumps 15.5%: Will It Continue to Soar?

Arcus Biosciences, Inc. (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...

6 months ago - Zacks Investment Research

Why Arcus Biosciences' Big Reveal Wasn't Very Exciting

No news from Arcus Biosciences is bad news for the company and other industry heavyweights.

6 months ago - The Motley Fool

Here's Why Arcus Biosciences Stock Is Rising Today

Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.

6 months ago - The Motley Fool

Arcus stock jumps 19% after announcing it will move forward with trial for lung-cancer treatment

Shares of Arcus Biosciences Inc. gained 19.8% in trading on Thursday, the day after the company said its experimental lung-cancer PD-L1 treatment demonstrated clinical activity in an open-label, Phase 2...

6 months ago - Market Watch